BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Macular degeneration and retinal disease clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for macular degeneration: 209 (134 sponsors; 31 newly posted in the last 180 days, 2 stopped in the last 180 days; 21 new-entrant sponsors). Momentum score 17.2, rank 35 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 5, Phase 1 26, Phase 2 70, Phase 3 50, Phase 4 4, N/A 54.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Hoffmann-La Roche | 9 | NA 3, P3 4, P4 1, P2 1 | 0 | 2 |
| AbbVie ABBV | 7 | P2 4, P3 3 | 0 | 1 |
| Kodiak Sciences Inc KOD | 3 | P3 3 | 0 | 2 |
| Ocular Therapeutix, Inc. OCUL | 3 | P3 3 | 0 | 1 |
| Adverum Biotechnologies, Inc. | 5 | P2 2, P3 2, NA 1 | 1 | 1 |
| 4D Molecular Therapeutics FDMT | 3 | P3 2, P2 1 | 0 | 1 |
| EyeBiotech Ltd. | 3 | P3 2, P2 1 | 0 | 0 |
| Ocugen OCGN | 3 | P2 1, P3 2 | 1 | 0 |
| Regeneron Pharmaceuticals REGN | 3 | P1 1, P3 2 | 0 | 0 |
| Annexon, Inc. ANNX | 2 | P3 2 | 1 | 0 |
| Belite Bio, Inc BLTE | 2 | P3 2 | 0 | 0 |
| EyePoint Pharmaceuticals, Inc. EYPT | 2 | P3 2 | 0 | 0 |
| Merck Sharp & Dohme LLC MRK new entrant | 2 | P3 2 | 2 | 0 |
| Ollin Biosciences, Inc. new entrant | 2 | P3 2 | 2 | 0 |
| Alkeus Pharmaceuticals, Inc. | 3 | P2 2, P3 1 | 0 | 0 |
| Innostellar Biotherapeutics Co.,Ltd | 3 | P2 1, P3 1, P1 1 | 0 | 0 |
| Amgen AMGN new entrant | 1 | P3 1 | 1 | 0 |
| AO GENERIUM new entrant | 1 | P3 1 | 1 | 0 |
| BioDlink Biopharm Co., Ltd. | 1 | P3 1 | 0 | 0 |
| Innovent Biologics (Suzhou) Co. Ltd. | 1 | P3 1 | 0 | 1 |
| Janssen Research & Development, LLC | 1 | P3 1 | 0 | 0 |
| Mighty Therapeutics Inc. new entrant | 1 | P3 1 | 1 | 0 |
| Outlook Therapeutics, Inc. OTLK | 1 | P3 1 | 0 | 0 |
| Qilu Pharmaceutical Co., Ltd. | 1 | P3 1 | 0 | 1 |
| RemeGen Co., Ltd. new entrant | 1 | P3 1 | 1 | 0 |
New-entrant sponsors: Merck Sharp & Dohme LLC, Ollin Biosciences, Inc., Amgen, AO GENERIUM, Mighty Therapeutics Inc., RemeGen Co., Ltd..
Recently stopped trials
- NCT06961370 Hoffmann-La Roche - terminated: The study was terminated prematurely by the Sponsor due to observation of dose-limiting adverse events meeting the protocol-defined stopping A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO76693
- NCT02479386 Hoffmann-La Roche - terminated: A Study of Disease Progression in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2/P3 | AbbVie ABBV | NCT04704921 Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | AMD; nAMD; Wet Age-related Macular Degeneration; wAMD; Wet AMD; CNV; Neovascular AMD; Neovascular Ag | active not recruiting | 671 |
| 2026-12 est. | P2 | jCyte, Inc | NCT06912633 Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP) | Retinitis Pigmentosa | active not recruiting | 31 |
| 2026-12 est. | P3 | Qilu Pharmaceutical Co., Ltd. | NCT07489586 A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration | Neovascular Age-Related Macular Degeneration (nAMD) | not yet recruiting | 356 |
| 2026-12-01 est. | P3 | Shanghai Vitalgen BioPharma Co., Ltd. | NCT06699108 Study to Evaluate the Efficacy and Safety of VGR-R01 Gene Therapy in Patients With Bietti Crystalline Dystrophy | Bietti Crystalline Dystrophy; Inherited Retinal Diseases | active not recruiting | 45 |
| 2026-12-22 est. | P3 | Adverum Biotechnologies, Inc. | NCT06856577 Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration | Neovascular Age-Related Macular Degeneration (nAMD); Wet AMD | active not recruiting | 311 |
| 2026-12-28 est. | P1/P2 | Chengdu Origen Biotechnology Co., Ltd. | NCT05672121 Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD) | Age-Related Macular Degeneration | recruiting | 42 |
| 2026-12-30 est. | P1/P2 | Bionic Sight LLC | NCT04278131 BS01 in Patients With Retinitis Pigmentosa | Retinitis Pigmentosa | recruiting | 20 |
| 2026-12-31 est. | P2 | Innovent Biologics Technology Limited (Shanghai R&D Center) | NCT06908876 A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema(DME) | Diabetic Macular Oedema | active not recruiting | 150 |
| 2027-01 est. | P1/P2 | Skyline Therapeutics (US) Inc. | NCT05986864 Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD) | Neovascular Age-related Macular Degeneration | recruiting | 68 |
| 2027-01-08 est. | P3 | Ocular Therapeutix, Inc. OCUL | NCT06495918 Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration | Neovascular Age-related Macular Degeneration | active not recruiting | 825 |
| 2027-01-11 est. | P2/P3 | EyeBiotech Ltd. | NCT06957080 A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME | Diabetic Macular Edema (DME) | active not recruiting | 1054 |
| 2027-01-31 est. | P3 | iRenix Medical, Inc. | NCT05750589 Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections | Retinal Disease | not yet recruiting | 240 |
| 2027-02 est. | P1/P2 | SparingVision | NCT05748873 Promising ROd-cone DYstrophy Gene therapY | Retinitis Pigmentosa | active not recruiting | 33 |
| 2027-02 est. | P3 | Kodiak Sciences Inc KOD | NCT06996080 A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE | Macular Edema Secondary to Inflammation | recruiting | 300 |
| 2027-02-04 est. | P3 | Hoffmann-La Roche | NCT04657289 A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age | Neovascular Age-related Macular Degeneration (nAMD) | active not recruiting | 451 |
| 2027-02-07 est. | P1/P2 | Intra-IMMUSG Pte Ltd | NCT07547228 A Study of PRL3-zumab in Neovascular Age-related Macular Degeneration (nAMD) | Neovascular Age Related Macular Degeneration | recruiting | 15 |
| 2027-02-12 est. | P3 | Ocugen OCGN | NCT06388200 A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa | Retinitis Pigmentosa | active not recruiting | 140 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11 est. | P2 | SciNeuro | NCT07199777 A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME Patients | Diabetic Macular Edema; DME | not yet recruiting | 60 |
| 2026-11 est. | P2 | Kiora Pharmaceuticals, Inc. KPRX | NCT06825702 Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema | Macular Edema | recruiting | 28 |
| 2026-10-31 est. | P2 | Neurimmune AG | NCT07213583 Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM | Amyloid Transthyretin Cardiomyopathy | active not recruiting | 35 |
| 2026-10-31 est. | P2 | Kyowa Kirin Co., Ltd. | NCT06116916 Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema | Diabetic Macular Edema (DME) | active not recruiting | 185 |
| 2026-10-26 | P2 | Boehringer Ingelheim | NCT06722157 A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy | Macular Degeneration, Age-related; Geographic Atrophy | completed | 202 |
| 2026-10-15 est. | P1/P2 | Eclipse Life Sciences, Inc. | NCT06536491 EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema | Diabetic Macular Edema | active not recruiting | 75 |
| 2026-10-13 | P2 | AbbVie ABBV | NCT04514653 RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) | Neovascular Age-Related Macular Degeneration (nAMD) | active not recruiting | 146 |
| 2026-10-01 | P2 | Qlaris Bio, Inc. | NCT07354477 Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation | Non-proliferative Diabetic Retinopathy (NPDR); Open-angle Glaucoma (OAG); Normal Tension Glaucoma (N | completed | 9 |
| 2026-10 est. | P3 | AbbVie ABBV | NCT05407636 Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD | AMD; nAMD; Wet Age-related Macular Degeneration; wAMD; WetAMD; CNV | active not recruiting | 735 |
| 2026-09-30 est. | P2 | Beijing Anlong Biopharmaceutical Co., Ltd. | NCT06839339 Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD | Wet Age-related Macular Degeneration (wAMD) | not yet recruiting | 40 |
| 2026-09-22 | P2 | Samsung Bioepis Co., Ltd. | NCT07844343 A Trial to Evaluate the Safety and Usability of the SB15 PFS in Trial Participants With AMD, Macular Oedema Secondary to RVO, or Diabetic Macular Oedema | Neovascular Age-related Macular Degeneration; Macular Oedema Secondary to RVO; Diabetic Macular Oede | completed | 33 |
| 2026-09-09 | P3 | EyePoint Pharmaceuticals, Inc. EYPT | NCT06683742 A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56 | Wet Age Related Macular Degeneration; wAMD | active not recruiting | 400 |
| 2026-09-02 | P3 | Kodiak Sciences Inc KOD | NCT06556368 A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-re | Wet Age-related Macular Degeneration | active not recruiting | 667 |
| 2026-09 est. | P3 | Rophibio, Inc. | NCT06470373 A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration | Neovascular Age-related Macular Degeneration (nAMD) | not yet recruiting | 434 |
| 2026-09 est. | P3 | Salutaris Medical Devices, Inc. | NCT05251636 Adjunct Episcleral Brachytherapy for PCV | Age-Related Macular Degeneration; Polypoid Choroidal Vasculopathy | not yet recruiting | 159 |
| 2026-09 est. | P3 | Eidos Therapeutics, a BridgeBio company | NCT04882735 Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN) | Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy | withdrawn | |
| 2026-08-30 est. | P2 | Innovent Biologics Technology Limited (Shanghai R&D Center) | NCT07275840 A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD | Neovascular Age-related Macular Degeneration | recruiting | 800 |
| 2026-08-30 est. | P3 | Beletalent (Zhuhai) Pharmaceutical Co., Ltd | NCT06817265 Clinical Study on the Efficacy and Safety of TNTL in the Treatment of Non-proliferative Diabetic Retinopathy | Non-Proliferative Diabetic Retinopathy | recruiting | 360 |
| 2026-08-25 | P1/P2 | Hoffmann-La Roche | NCT04567303 Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration | Macular Degeneration | completed | 177 |
| 2026-08-19 | P2 | Novartis Pharmaceuticals NVS | NCT05230537 A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration | Age-Related Macular Degeneration | completed | 168 |
| 2026-08-12 | P2 | EnnovaBio | NCT06708260 A Phase 2 Study to Evaluate the Efficacy and Safety of ENN0403 in Subjects With DME | Diabetic Macular Edema (DME) | completed | 60 |
| 2026-07-31 est. | P2 | OHB Neonatology Ltd. | NCT03253263 A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants | Bronchopulmonary Dysplasia; Chronic Lung Disease of Prematurity; Intraventricular Hemorrhage; Retino | active not recruiting | 295 |
| 2026-07-14 | P2/P3 | EyeBiotech Ltd. | NCT06571045 A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME | Diabetic Macular Edema (DME) | active not recruiting | 984 |
| 2026-07-13 | P3 | EyePoint Pharmaceuticals, Inc. EYPT | NCT06668064 A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56 | Wet Age Related Macular Degeneration; wAMD | active not recruiting | 400 |
| 2026-07 est. | P2 | Annexin Pharmaceuticals AB | NCT07259928 Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion | Non-Proliferative Diabetic Retinopathy; Retinal Vein Occlusion | recruiting | 12 |
| 2026-06-30 est. | P2/P3 | Beacon Therapeutics BBT | NCT04850118 A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP | X-Linked Retinitis Pigmentosa | active not recruiting | 85 |
| 2026-06-18 | P2 | AbbVie ABBV | NCT04567550 RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular | Diabetic Retinopathy (DR); Center-Involved Diabetic Macular Edema (CI-DME) | completed | 139 |
| 2026-06-03 | P2 | Kyowa Kirin Co., Ltd. | NCT06116890 Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration | Neovascular Age-Related Macular Degeneration (nAMD) | completed | 170 |
| 2026-06 est. | P3 | RemeGen Co., Ltd. | NCT05885503 Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema | Diabetic Macular Edema | unknown | 316 |
| 2026-06 est. | P1/P2 | 4D Molecular Therapeutics FDMT | NCT04517149 4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP) | X-Linked Retinitis Pigmentosa | active not recruiting | 21 |
| 2026-05-27 | P2 | Sam Chun Dang Pharm. Co. Ltd. | NCT07501052 Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic | Neovascular (Wet) Age-Related Macular Degeneration; Retinal Vein Occlusion; Diabetic Macular Edema; | completed | 33 |
| 2026-05-27 | P1/P2 | Elisigen, Inc. | NCT05984927 NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration | Age-Related Macular Degeneration | active not recruiting | 20 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "macular degeneration"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.